The class action lawsuit was brought on behalf of  users of a diabetes drug ACTOS (pioglitazone hydrochloride) residing in  Quebec against the manufacturers and distributors of ACTOS, Takeda  Pharmaceutical Company, and its affiliates, and Eli Lilly.

ACTOS was approved for sale in Canada in August, 2000 to control blood  sugar levels in people with Type 2 (non insulin-dependant) diabetes. A  June 2011 study reported to the FDA found a clear link between pioglitazone and increased bladder cancer risk. As a result, the FDA in  the U.S. issued a warning, now incorporated on the drug’s label, that  use of ACTOS for more than one year may be associated with an increased  risk of bladder cancer. French and German drug regulators suspended sales of ACTOS entirely following the results of similar studies in  those countries.

CLASS:   users of a diabetes drug ACTOS (pioglitazone hydrochloride) residing in  Quebec